عام

• Adrenoleukodystrophy

  Stem cell treatment offers potential benefits for adrenoleukodystrophy (ALD) by replacing defective cells with healthy ones, thereby potentially halting disease progression and improving neurological function.

  A 2017 phase 2–3 clinical study in the New England Journal of Medicine found that hematopoietic stem-cell gene therapy (Lenti-D) stabilized cerebral demyelination, leaving most boys with early cerebral adrenoleukodystrophy alive and free of major functional disability.

• Alzheimer’s Disease

  Stem cell therapy may help treat Alzheimer's disease by replacing damaged neurons and promoting the release of neurotrophic factors, which support neuron survival and function.

  A 2019 preclinical study in the Journal of Alzheimer's Disease found that transplanting mesenchymal stem cells into Alzheimer's-model mice reduced amyloid-beta accumulation and improved spatial memory by enhancing microglial clearance.

• Amyotrophic Lateral Sclerosis

  Stem cell treatment may benefit ALS patients by protecting motor neurons and reducing inflammation.

  A 2016 phase 1/2 clinical trial in JAMA Neurology found that transplantation of autologous neurotrophic-factor-secreting mesenchymal stem cells was safe and was associated with a slowed rate of functional decline in most treated ALS patients.

• Arthritis / Osteoarthritis

  MSCs can aid in arthritis treatment by regenerating damaged cartilage, reducing inflammation, and modulating the immune response.

  A 2017 clinical study (7-year follow-up) in Stem Cells Translational Medicine found that umbilical-cord-blood mesenchymal stem cells with a hydrogel scaffold regenerated hyaline-like cartilage and gave durable pain and function improvement in osteoarthritic knees.

• Cartilage Repair

  Stem cell therapy can promote cartilage repair by differentiating into chondrocytes and producing extracellular matrix.

  A 2014 clinical case series in the American Journal of Sports Medicine found that, after mesenchymal stem cell implantation in osteoarthritic knees, second-look arthroscopy showed cartilage repair tissue alongside significant clinical improvement.

• Cerebral Hemorrhage (sequela)

  Stem cells may help in the recovery from cerebral hemorrhage by promoting neurogenesis, reducing inflammation, and enhancing angiogenesis.

  A 2022 review in Frontiers in Cellular Neuroscience reported that mesenchymal stem cell transplantation improves recovery after intracerebral hemorrhage by promoting neurogenesis and angiogenesis and reducing neuroinflammation in animal models.

• Critical Limb Ischemia

  Stem cell treatment can improve blood flow and promote tissue regeneration in critical limb ischemia.

  A 2018 meta-analysis of 23 randomized controlled trials (962 patients) in Stem Cells International found that autologous stem cell therapy improved limb perfusion and ulcer healing and reduced amputation rates in critical limb ischemia.

• Covid-19

  MSCs have shown promise in treating severe COVID-19 by modulating the immune response and reducing cytokine storm effects.

  A 2020 clinical pilot study in Aging and Disease found that intravenous mesenchymal stem cells improved pulmonary outcomes in COVID-19 pneumonia patients while lowering TNF-alpha and overactive cytokine-secreting immune cells.

• Crohn’s Disease

  Stem cell therapy may benefit Crohn's disease by promoting mucosal healing and reducing inflammation.

  A 2016 phase 3 randomized, double-blind, placebo-controlled trial (ADMIRE-CD) in The Lancet found that local injection of allogeneic adipose-derived mesenchymal stem cells significantly increased remission of refractory perianal fistulas in Crohn's disease.

• Diabetes Type 1

  Stem cells can potentially regenerate insulin-producing beta cells in Type 1 diabetes, improving glycemic control.

  A 2009 clinical trial in JAMA found that autologous nonmyeloablative hematopoietic stem cell transplantation raised C-peptide and enabled insulin independence in most patients with newly diagnosed type 1 diabetes.

• Diabetes Type 2

  Stem cell therapy may help Type 2 diabetes by enhancing insulin sensitivity and modulating chronic inflammation.

  A 2022 double-blind randomized placebo-controlled trial in Stem Cell Research & Therapy found that umbilical-cord mesenchymal stem cells significantly improved insulin sensitivity and lowered HbA1c in adults with type 2 diabetes.

• Diabetic Retinopathy

  Stem cells may help treat diabetic retinopathy by regenerating damaged retinal cells and improving vascular health.

  A 2019 preclinical study in Experimental Eye Research found that human CD34+ stem cells homed to the retinal vasculature and preserved retinal vascular density in a mouse model of diabetic retinopathy.

• Diabetic Foot

  Stem cell therapy can promote wound healing and improve vascularization in diabetic foot ulcers.

  A 2011 double-blind randomized controlled trial in Diabetes Research and Clinical Practice found that bone-marrow mesenchymal stem cell transplantation improved diabetic foot ulcer healing and limb perfusion.

• Down Syndrome

  Stem cell therapy may help improve cognitive function and reduce neurodegeneration in Down syndrome.

  A 2012 preclinical study in Experimental Gerontology found that hippocampal neural-progenitor implantation modestly improved learning and memory and reduced tau aggregation in a Down-syndrome mouse model.

• Cortical Dysplasia (Malformations of Cortical Development)

  Cortical dysplasia — a group of congenital brain malformations sometimes grouped as “encephalo-dysplasia” — most often causes drug-resistant epilepsy; stem cell approaches aim to restore the brain's inhibitory circuits.

  A 2013 preclinical study in Nature Neuroscience found that transplanted inhibitory (GABAergic) neuron progenitors integrated into the brain and substantially reduced seizures while improving learning and behaviour in epileptic mice.

• Encephalomyelitis

  Stem cell therapy may help treat encephalomyelitis by reducing inflammation and promoting tissue repair.

  A 2010 study in the Journal of Neuropathology & Experimental Neurology found that intravenous mesenchymal stem cells reduced demyelination and clinical disease severity in mice with experimental autoimmune encephalomyelitis (the multiple sclerosis model).

• Glaucoma

  Stem cells can potentially regenerate damaged optic nerve cells and improve vision in glaucoma.

  A 2015 review in Neural Regeneration Research reported that, in rodent glaucoma models, mesenchymal stem cells increased retinal ganglion cell survival and axon regeneration, mainly through paracrine neurotrophic factors.

• Global Developmental Delay

  Stem cell therapy may help improve neurodevelopment and cognitive function in children with global developmental delay.

  A 2023 prospective clinical trial in Stem Cells and Development found that a single allogeneic umbilical-cord-blood infusion was safe and was associated with improved development, language and daily-living scores in children with global developmental delay.

• Hearing Loss (sensorineural)

  Stem cells can potentially regenerate damaged hair cells and auditory neurons, improving hearing in sensorineural hearing loss.

  A 2018 phase 1 clinical trial in the Journal of Audiology & Otology found that intravenous autologous umbilical-cord-blood infusion was safe and reduced auditory brainstem-response thresholds in a subset of children with sensorineural hearing loss.

• Huntington’s Disease

  Stem cell therapy may help treat Huntington’s disease by replacing damaged neurons and modulating neuroinflammation.

  A 2012 animal study in PLoS Currents found that neurotrophic-factor-secreting mesenchymal stem cells temporarily improved motor function and extended survival in a mouse model of Huntington's disease.

• Hypoxic-Ischemic Encephalopathy (HIE)

  Stem cells can potentially aid in the recovery from HIE by promoting neurogenesis and reducing inflammation.

  A 2020 study in Frontiers in Cellular Neuroscience found that mesenchymal-stem-cell-derived extracellular vesicles reduced neuroinflammation and promoted neural progenitor proliferation in a neonatal hypoxic-ischemic brain-injury mouse model.

• Inflammatory Bowel Disease

  Stem cell therapy may help treat inflammatory bowel disease by promoting mucosal healing and reducing inflammation.

  A 2017 randomized controlled trial in Gut and Liver found that intravenous umbilical-cord mesenchymal stem cells significantly reduced disease activity and endoscopic mucosal inflammation in patients with Crohn's disease.

• Leber’s Hereditary Optic Neuropathy

  Stem cells can potentially regenerate damaged optic nerve cells and improve vision in Leber’s hereditary optic neuropathy.

  A 2016 open-label clinical study (SCOTS) in Neural Regeneration Research reported visual-acuity gains after autologous bone-marrow stem cell injection in patients with Leber's hereditary optic neuropathy.

• Liver Cirrhosis

  Stem cell therapy may help treat liver cirrhosis by promoting liver regeneration and reducing fibrosis.

  A 2021 randomized controlled trial in Hepatology International found that umbilical-cord mesenchymal stem cell infusion improved liver function and increased long-term survival in patients with decompensated liver cirrhosis.

• Lower Limb Ischemia

  Stem cells can improve blood flow and promote tissue regeneration in lower limb ischemia.

  A 2012 meta-analysis of randomized controlled trials in Catheterization and Cardiovascular Interventions found that autologous bone-marrow stem cell transplantation improved blood flow and reduced amputation rates in critical/lower-limb ischemia.

• Lupus

  Stem cell therapy may help treat lupus by modulating the immune response and promoting tissue repair.

  A 2014 multicenter clinical study in Arthritis Research & Therapy found that umbilical-cord mesenchymal stem cell transplantation produced major or partial clinical responses in 60% of 40 patients with active, refractory systemic lupus erythematosus.

• Macular Degeneration

  Stem cells can potentially regenerate damaged retinal cells and improve vision in macular degeneration.

  A 2012 clinical study in The Lancet found that subretinal transplantation of human embryonic stem cell-derived retinal pigment epithelium was safe and associated with measurable visual-acuity improvement in patients with macular degeneration.

• Multiple System Atrophy

  Stem cell therapy may help treat multiple system atrophy by protecting neurons and reducing neuroinflammation.

  A 2012 randomized, double-blind, placebo-controlled trial in Annals of Neurology found that autologous mesenchymal stem cell therapy slowed clinical progression in patients with cerebellar-type multiple system atrophy.

• Neuropathic Pain

  Stem cells can potentially alleviate neuropathic pain by promoting nerve regeneration and reducing inflammation.

  A 2014 clinical case series in the Journal of Pain Research found that local injection of autologous adipose-derived mesenchymal stem cells reduced pain scores and analgesic use over six months in patients with neuropathic pain.

• Parkinson’s Disease

  Stem cell therapy may help treat Parkinson’s disease by replacing damaged dopaminergic neurons and modulating neuroinflammation.

  A 2025 phase 1 clinical trial in Nature found that transplantation of human embryonic stem cell-derived dopaminergic neuron progenitors was safe, with surviving grafts on PET imaging and stable or improved motor scores in Parkinson's patients at 18 months.

• Peripheral Neuropathy

  Stem cells can potentially regenerate damaged peripheral nerves and improve sensory and motor function.

  A 2015 study in Cell Transplantation found that mesenchymal stem cells restored motor and sensory nerve conduction velocities and improved nerve myelination in diabetic rats with peripheral neuropathy.

• Primary Lateral Sclerosis

  Stem cell therapy may help treat primary lateral sclerosis by protecting motor neurons and reducing neuroinflammation.

  Primary lateral sclerosis belongs to the motor neuron disease family alongside ALS, where most stem cell research has focused: a 2016 phase 1/2 trial in JAMA Neurology found that neurotrophic-factor-secreting mesenchymal stem cells were safe and were associated with a slowed rate of functional decline in ALS patients.

• Psoriasis

  Stem cells can potentially modulate the immune response and reduce inflammation in psoriasis.

  A 2022 phase 1/2a clinical study in Signal Transduction and Targeted Therapy found that umbilical-cord mesenchymal stem cell infusions improved psoriasis severity and increased regulatory T cells while reducing Th17 cells.

• Renal Insufficiency

  Stem cell therapy may help treat renal insufficiency by promoting kidney regeneration and reducing fibrosis.

  A 2023 randomized, placebo-controlled trial (NEPHSTROM) in the Journal of the American Society of Nephrology found that a single infusion of allogeneic mesenchymal stromal cells was safe and slowed kidney-function decline in patients with progressive diabetic kidney disease.

• Retinitis Pigmentosa

  Stem cells can potentially regenerate damaged retinal cells and improve vision in retinitis pigmentosa.

  A 2020 phase 1/2 clinical trial in Stem Cells and Development found that intravenous umbilical-cord mesenchymal stem cells were safe and maintained or partially improved visual acuity in most patients with advanced retinitis pigmentosa.

• Retinopathy of Prematurity

  Stem cell therapy may help treat retinopathy of prematurity by promoting retinal regeneration and reducing inflammation.

  A 2021 study in Frontiers in Cell and Developmental Biology found that mesenchymal stromal cells promoted healthy retinal revascularization and suppressed pathological neovascularization in a mouse oxygen-induced retinopathy model (the standard retinopathy-of-prematurity model).

• Rheumatoid Arthritis

  Stem cells can potentially modulate the immune response and reduce inflammation in rheumatoid arthritis.

  A 2013 clinical study in Stem Cells and Development found that umbilical-cord mesenchymal stem cell therapy reduced disease activity and inflammatory markers (TNF-alpha, IL-6) while raising regulatory T cells in 172 patients with active rheumatoid arthritis.

• Syringomyelia

  Stem cells can potentially promote spinal cord repair and reduce cyst formation in syringomyelia.

  A 2022 preclinical study in eBioMedicine found that transplanted stem cell-derived neuroepithelial stem cells reduced intraspinal cyst (syrinx) volume and promoted spinal-cord repair in a rat model of syringomyelia.

• Ulcerative Colitis

  Stem cell therapy may help treat ulcerative colitis by promoting mucosal healing and reducing inflammation.

  A 2016 randomized controlled trial in Experimental and Therapeutic Medicine found that umbilical-cord mesenchymal stem cell infusion improved mucosal inflammation and Mayo scores in patients with moderate-to-severe ulcerative colitis.

• Viral Encephalitis

  Stem cells can potentially aid in the recovery from viral encephalitis by promoting neurogenesis and reducing inflammation.

  A 2017 study in Stem Cell Research & Therapy found that mesenchymal stem cells reduced neuroinflammation and improved survival in a mouse model of Japanese encephalitis virus infection.

No condition matches your search — but our list is not exhaustive. Contact our medical team about your specific diagnosis.